{"entity": "researcher", "timestamp": "2026-09-08T10:05:38.751Z", "family": "Jernstr\u00f6m", "given": "Helena", "initials": "H", "orcid": "0000-0002-2301-5147", "affiliations": ["Division of Oncology, Department of Clinical Sciences in Lund, Lund University and Sk\u00e5ne University Hospital, Barngatan 4, 221 85, Lund, Sweden. helena.jernstrom@med.lu.se."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/964c51ce10fd4c658f31ceae00bb926a.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/964c51ce10fd4c658f31ceae00bb926a"}}, "publications": [{"entity": "publication", "iuid": "487a9ff12bab4e30ba59c83a10d34517", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/487a9ff12bab4e30ba59c83a10d34517.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/487a9ff12bab4e30ba59c83a10d34517"}}, "title": "Caveolin-1 genotypes as predictor for locoregional recurrence and contralateral disease in breast cancer.", "authors": [{"family": "Godina", "given": "Christopher", "initials": "C"}, {"family": "Tryggvadottir", "given": "Helga", "initials": "H"}, {"family": "Bosch", "given": "Ana", "initials": "A"}, {"family": "Borgquist", "given": "Signe", "initials": "S"}, {"family": "Belting", "given": "Mattias", "initials": "M"}, {"family": "Isaksson", "given": "Karolin", "initials": "K"}, {"family": "Jernstr\u00f6m", "given": "Helena", "initials": "H", "orcid": "0000-0002-2301-5147", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/964c51ce10fd4c658f31ceae00bb926a.json"}}], "type": "journal article", "published": "2023-06-00", "journal": {"title": "Breast Cancer Res. Treat.", "issn": "1573-7217", "volume": "199", "issue": "2", "pages": "335-347", "issn-l": "0167-6806"}, "abstract": "Caveolin-1 (CAV1) has been implicated in breast cancer oncogenesis and metastasis and may be a potential prognosticator, especially for non-distant events. CAV1 functions as a master regulator of membrane transport and cell signaling. Several CAV1 SNPs have been linked to multiple cancers, but the prognostic impact of CAV1 SNPs in breast cancer remains unclear. Here, we investigated CAV1 polymorphisms in relation to clinical outcomes in breast cancer.\n\nA cohort of 1017 breast cancer patients (inclusion 2002-2012, Sweden) were genotyped using Oncoarray by Ilumina. Patients were followed for up to 15 years. Five out of six CAV1 SNPs (rs10256914, rs959173, rs3807989, rs3815412, and rs8713) passed quality control and were used for haplotype construction. CAV1 genotypes and haplotypes in relation to clinical outcomes were assessed with Cox regression and adjusted for potential confounders (age, tumor characteristics, and adjuvant treatments).\n\nOnly one SNP was associated with lymph node status, no other SNPs or haplotypes were associated with tumor characteristics. The CAV1 rs3815412 CC genotype (5.8% of patients) was associated with increased risk of contralateral breast cancer, adjusted hazard ratio (HRadj) 4.26 (95% CI 1.86-9.73). Moreover, the TTACA haplotype (13% of patients) conferred an increased risk for locoregional recurrence HRadj 2.24 (95% CI 1.24-4.04). No other genotypes or haplotypes were associated with clinical outcome.\n\nCAV1 polymorphisms were associated with increased risk for locoregional recurrence and contralateral breast cancer. These findings may identify patients that could derive benefit from more tailored treatment to prevent non-distant events, if confirmed.", "doi": "10.1007/s10549-023-06919-x", "pmid": "37017811", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC10175335"}, {"db": "pii", "key": "10.1007/s10549-023-06919-x"}], "notes": [], "created": "2026-08-21T11:07:39.756Z", "modified": "2026-08-21T11:07:39.833Z"}]}